Vivos Therapeutics is filing a patent on revised clinical methods and protocols that show promise in treating obstructive sleep apnea.
The Vivos Method seeks to treat OSA through a combination of Vivos oral appliances and devices and clinical methods and protocols.
Vivos decided to file a patent based on early field data that showed an additional 58% improvement in Apnea Hypopnea Index score reductions in OSA patients who had received Vivos Method treatment with the revised clinical protocols.
The Vivos Continuous Clinical Improvement Program is a multidisciplinary effort by numerous medical, dental, and other healthcare professionals who treat OSA.
Clinical enhancements and outcomes are overseen by Vivos personnel working in close collaboration with the members of Vivos medical and clinical advisory boards, outside university clinicians and researchers, and through collaboration with other companies.
“As an emerging market leader in technologies and protocols to treat patients with OSA, we continually seek to find new and innovative ways to further improve both patient experiences and clinical outcomes,” said Kirk Huntsman, Vivos chairman and chief executive officer. “We believe these new methods and protocols are not only patentable but will enhance the positive experience that Vivos Method patients have reported.”